Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation.

Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C. · 2016

Read Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. by Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4868820.txt.

Introduction

Christopher J. Tape and co-authors showed in 2016 that a cancer-driving KRAS fault signals through nearby support cells, not only within tumor cells. Mutant KRAS is a classic engine of pancreatic cancer. The team tagged proteins by cell type and read thousands of signal marks in tumor and fibroblast cells grown together, tracing who tells whom.

Tumor KRAS woke the fibroblasts, which then sent signals back that doubled the tumor cell's active signal nodes and used extra enzymes. The returned signal boosted growth, survival, and cell energy through a named growth axis. Oncogene action is thus a two-way street between cell types, and drug plans should treat it that way.

Catalog record

CREATORTape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G, Lauffenburger DA, Jørgensen C.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4868820

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation By Christopher J Tape, Stephanie Ling, Maria Dimitriadi, Kelly M McMahon, Jonathan D Worboys, Hui Sun Leong, Ida C Norrie, Crispin J Miller, George Poulogiannis, Douglas A Lauffenburger, Claus Jørgensen Published in: Cell DOI: 10.1016/j.cell.2016.03.029 ABSTRACT Summary Oncogenic mutations regulate signaling within both tumor cells and adjacent stromal cells. Here, we show that oncogenic KRAS (KRASG12D) also regulates tumor cell signaling via stromal cells. By combining cell-specific proteome labeling with multivariate phosphoproteomics, we analyzed heterocellular KRASG12D signaling in pancreatic ductal adenocarcinoma (PDA) cells. Tumor cell KRASG12D engages heterotypic fibroblasts, which subsequently instigate reciprocal signaling in the tumor cells. Reciprocal signaling employs additional kinases and doubles the number of regulated signaling nodes from cell-autonomous KRASG12D. Consequently, reciprocal KRASG12D produces a tumor cell phosphoproteome and total proteome that is distinct from cell-autonomous KRASG12D alone. Reciprocal signaling regulates tumor cell proliferation and apoptosis and increases mitochondrial capacity via an IGF1R/AXL-AKT axis. These results demonstrate that oncogene signaling should be viewed as a heterocellular process and that our existing cell-autonomous perspective underrepresents the extent of oncogene signaling in cancer. Video Abstract INTRODUCTION Solid cancers are heterocellular systems containing both tumor cells and stromal cells. Coercion of stromal cells by tumor cell oncogenes profoundly impacts cancer biology (Friedl and Alexander, 2011, Quail and Joyce, 2013) and aberrant tumor-stroma signaling regulates many hallmarks of cancer (Hanahan and Weinberg, 2011). While individual oncogene-driven regulators of tumor-stroma signaling have been identified, the propagation of oncogene-dependent signals throughout a heterocellular system is poorly understood. Consequently, our perspective of oncogenic signaling is biased toward how oncogenes regulate tumor cells in isolation (Kolch et al., 2015). In a heterocellular cancer, tumor cell oncogenes drive aberrant signaling both within tumor cells (cell-autonomous signaling) and adjacent stromal cells (non-cell-autonomous signaling) (Croce, 2008, Egeblad et al., 2010). As different cell types process signals via distinct pathways (Miller-Jensen et al., 2007), heterocellular systems (containing different cell types) theoretically provide increased signal processing capacity over homocellular systems (containing a single cell type). By extension, oncogene-dependent signaling can theoretically engage additional signaling pathways in a heterocellular system when compared to a homocellular system. However, to what extent activated stromal cells reciprocally regulate tumor cells beyond cell-autonomous signaling is not well understood. We hypothesized that the expanded signaling capacity provided by stromal heterocellularity allows oncogenes to establish a differential reciprocal signaling state in tumor cells. To test this hypothesis, we studied oncogenic KRAS (KRASG12D) signaling in pancreatic ductal adenocarcinoma (PDA). KRAS is one of the most frequently activated oncogenic drivers in cancer (Pylayeva-Gupta et al., 2011) and is mutated in >90% of PDA tumor cells (Almoguera et al., 1988). PDA is an extremely heterocellular malignancy—composed of mutated tumor cells, stromal fibroblasts, endothelial cells, and immune cells (Neesse et al., 2011). Crucially, the gross stromal pancreatic stellate cell (PSC) expansion observed in the PDA microenvironment is non-cell-autonomously controlled by tumor cell KRASG12D in vivo (Collins et al., 2012, Ying et al., 2012). As a result, understanding the heterocellular signaling consequences of KRASG12D is essential to comprehend PDA tumor biology. Comprehensive analysis of tumor-stroma signaling requires concurrent measurement of cell-specific phosphorylation events. Recent advances in proteome labeling now permit cell-specific phosphoproteome analysis in heterocellular systems (Gauthier et al., 2013, Tape et al., 2014a). Furthermore, advances in proteomic multiplexing enable deep multivariate phospho-signaling analysis (McAlister et al., 2012, Tape et al., 2014b). Here, we combine cell-specific proteome labeling, multivariate phosphoproteomics, and inducible oncogenic mutations to describe KRASG12D cell-autonomous, non-cell-autonomous, and reciprocal signaling across a heterocellular system. This study reveals KRASG12D uniquely regulates tumor cells via heterotypic stromal cells. By exploiting heterocellularity, reciprocal signaling enables KRASG12D to engage oncogenic signaling pathways beyond those regulated in a cell-autonomous manner. Expansion of KRASG12D signaling via stromal reciprocation suggests oncogenic communication should be viewed as a heterocellular process. RESULTS Tumor Cell KRASG12D Non-cell-autonomously Regulates Stromal Cells To investigate how KRASG12D supports heterocellular communication, we first analyzed tumor cell-secreted signals (using PDA tumor cells containing an endogenous doxycycline inducible KRASG12D) (Collins et al., 2012, Ying et al., 2012). Measuring 144 growth factors, cytokines, and receptors across three unique PDA isolations, we observed that KRASG12D increased secretion of GM-CSF, GCSF cytokines, and the growth morphogen sonic hedgehog (SHH) (Figure 1A). As SHH regulates pancreatic myofibroblast expansion (Collins et al., 2012, Fendrich et al., 2011, Thayer et al., 2003, Tian et al., 2009, Yauch et al., 2008), and ablation of SHH signaling reduces PDA tumor stroma in vivo (Lee et al., 2014, Olive et al., 2009, Rhim et al., 2014), we focused on understanding the trans-cellular signaling consequences of SHH. [Figure: Tumor Cell KRASG12D Non-cell-autonomously Regulates PSCs(A) Soluble growth factor/cytokine/receptor array of conditioned media from three iKRAS PDA cell isolations (KRASG12D/KRASWT) (hierarchical clustering). KRASG12D increases GM-CSF, GCSF, and SHH protein secretion.(B) SHH ELISA of PDA and PSC conditioned media. PSC do not secrete SHH, whereas KRASG12D induces SHH secretion from PDA tumor cells (two-tailed t test) (n = 3). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.(C) High-content imaging primary cilia quantification (via acetylated tubulin) for all cells (48 hr) (n = 3). PSCs and KRASWT PDA cells possess primary cilia, whereas KRASG12D do not; t test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.(D) PSCs and PDA cells (KRASG12D and KRASWT) transfected with a Gli1-luciferase reporter stimulated with SHH for 48 hr ± Smoothened (SMO-i) or Gli (Gli-i) inhibitors. Ligand-dependent SHH signaling (via canonical SMO and Gli activity) is only observed in PSCs and KRASWT PDA cells (n = 3). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.(E) PSCs transfected with Gli1-luciferase reporter co-cultured with PDA cells ± SHH inhibitory antibody (SHHi). PDA KRASG12D secreted SHH initiates non-cell-autonomous signaling in PSCs. RLU fold-difference versus PSC+Gli1-luciferase in mono-culture (n = 3) (blue = stimulation, black = inhibition). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.(F) PSC cytoplasmic, membrane, and secreted proteomes regulated by SHH (48 hr).(G) DAVID GO-enrichment analysis of SHH non-cell-autonomously regulated PSC proteome (p < E−06).(H and I) SHH upregulates IGF-1 and GAS6 protein in PSCs, but not in KRASG12D PDA cells. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.See also Figure S1 and Data S1.] As previously established, KRASG12D simultaneously induces SHH secretion (Collins et al., 2012, Lauth et al., 2010) (Figure 1B) and disrupts primary cilium in PDA cells (Figure 1C). Concordantly, PSCs and KRASWT PDA cells transduce canonical SHH signaling (via SMO-GLI), while KRASG12D cells do not (Figure 1D). This enables KRASG12D PDA cells to non-cell-autonomously signal to PSCs via SHH, while remaining insensitive to autocrine SHH (Figure 1E). Quantitative proteomic analysis revealed SHH induces widespread changes across the cytoplasmic, membrane, and secreted PSC proteome (Figures 1F, 1G, and S1A; Data S1). SHH upregulates multiple extracellular matrix components (collagens, MMPs, fibrillin-1, LOX)—suggesting KRASG12D controls PDA desmoplasia via SHH-activated PSCs. Notably, SHH also upregulates IGF1 and GAS6 across multiple PSC isolations but not in PDA cells (Figures 1H, 1I, and S1B). Since IGF1 and GAS6 are growth factors capable of activating the receptor tyrosine kinases (RTKs) IGF1R and AXL, respectively, this suggests that SHH-activation alters the intercellular signaling potential of PSCs. [Figure: SHH Regulates Cytoplasmic, Membrane, and Secreted PSC Proteomes, Related to Figure 1(A) Cellular heat map of regulated proteins

Read the complete text